Literature DB >> 24972584

Continuous ampicillin infusion as an alternative to intermittent infusion for adult inpatients: a case series.

Taku Ogawa1, Kei Kasahara2, Kazuro Ikawa3, Junichi Shigeta4, Yuko Komatsu1, Noriko Kuruno1, Kenji Uno1, Koichi Maeda1, Keiichi Mikasa1.   

Abstract

Intravenous ampicillin has been extensively used for various kinds of infections for more than fifty years. This drug is administered intermittently, which can result in missed or delayed drug administration and sleep interruption that can have a negative impact on the quality of life during hospitalization. Continuous infusion may solve these concerns. We reviewed the cases of five patients who were treated with continuous ampicillin infusions in our hospital. The ampicillin serum concentrations were from 11.3 to 32.8 μg/mL, which was above the ampicillin MICs of the causative organisms, ≤0.06 to 4 μg/mL. Although the dosages given of ampicillin varied in each case, the serum concentrations showed a strong correlation with creatinine clearance (r(2) = 0.91). All the patients improved at the time of discharge, or transfer to another hospital, with no significant complications during the continuous infusion. Continuous ampicillin infusion could be a better alternative for frequent intermittent infusion for adult inpatients with infections due to ampicillin-susceptible organisms.
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Keywords:  Ampicillin; Continuous infusion; Infective endocarditis

Mesh:

Substances:

Year:  2014        PMID: 24972584     DOI: 10.1016/j.jiac.2014.05.006

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  1 in total

1.  A Proof of Concept of the Usefulness of a TDM-Guided Strategy for Optimizing Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Ampicillin-Based Regimens in a Case Series of Patients with Enterococcal Bloodstream Infections and/or Endocarditis.

Authors:  Milo Gatti; Sara Tedeschi; Filippo Trapani; Stefania Ramirez; Rita Mancini; Maddalena Giannella; Pierluigi Viale; Federico Pea
Journal:  Antibiotics (Basel)       Date:  2022-08-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.